|
Nanobac Pharmaceuticals, Inc. - Comparative Business Analysis Snapshot
Business Description
Nanobac Pharmaceuticals, Inc.. The Group's principal activity is the research and development of therapeutic and diagnostic technologies relating to the pleomorphic pathogen known as nanobacterium sanguineum. The Group is biolifescience company which develops diagnostic tests for the detection of Nanobacterial infection, as well as medications that treat atherosclerosis and coronary heart disease. It has a commercially available serology test for the identification of nanobacterial antibodies and antigens. It also conducts biomedical research and clinical studies in the development of atherosclerosis, gall stones, chronic prostatitis, diabetes, arthritic spurs, cataracts, scleroderma, kidney cysts and kidney stones, certain breast pathology, polycystic kidney disease, solid tumor pathologies, immunosuppressed conditions, dental pulp stone, and neurodegenerative disease. It majorly operates in the United States and Finland.
Competitor Analysis
This analysis compares Nanobac Pharmaceuticals, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
